NCT03297424

Who might be able to join this trial:

• You have been diagnosed with an advanced solid tumor cancer (confirmed by tissue testing) that has not responded to previous treatments, or you have a type of blood cancer called non-Hodgkin's lymphoma (specifically diffuse large B-cell lymphoma or follicular lymphoma Grade 1–3A) that has come back or stopped responding after at least one prior treatment.
• You are 18 years of age or older.
• You are generally able to carry out daily activities with little or no limitation (your doctor can assess this using a standard scale called ECOG 0–1).
• Your heart, liver, kidneys, and other organs are functioning well enough, based on blood tests done within 10 days of starting treatment.
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before starting the study drug, and you must agree to use effective birth control from that point until 90 days after your last dose.
• If you are a woman who cannot become pregnant — either because you have had a surgical procedure or have been through menopause for at least 1 year — you may also be eligible.
• If you are a man who is able to father children, you must agree to use effective birth control during the study and for up to 90 days after your last dose.
• Any significant side effects from your previous cancer treatments must have cleared up before you can start this study (some exceptions, such as hair loss or mild nerve-related symptoms, are allowed).
• You are willing and able to sign a consent form and follow all study requirements.

Who may not be able to join:

• You have previously taken a type of drug called a bromodomain inhibitor (for example, OTX-015 or CPI-0610).
• You have an active, uncontrolled infection (fungal, bacterial, or viral) that is moderate or severe in nature.
• You have a condition where your immune system is attacking your own red blood cells or platelets.
• You have cancer that has spread to your brain or the lining around your brain and spinal cord, and it is causing symptoms or is not under control.
• You have a known or suspected allergy to the study drug or any other drug used in this trial.
• You have significant heart problems, such as an uncontrolled irregular heartbeat, uncontrolled high blood pressure, or a history of blood clots in your veins or arteries (people with well-controlled atrial fibrillation may still be eligible — confirm with trial site).
• You are unable to swallow pills, or you have a digestive condition that would prevent you from properly absorbing the study drug (such as severe nausea, a malabsorption condition, or major bowel surgery).
• You have a wound, ulcer, or bone fracture that is not healing.
• You are known to have HIV, active hepatitis B, or hepatitis C infection (some people with past hepatitis B exposure may still be eligible if certain blood test results are undetectable — confirm with trial site).
• You currently have another active cancer, with some exceptions such as certain treated skin cancers, early-stage cancers in remission for 2 or more years, low-risk prostate cancer meeting specific criteria, or any cancer from which you have been cancer-free for 3 or more years.
• You have liver metastases (cancer spread to the liver) covering more than half of the liver, or any single liver tumor larger than 5 cm.
• You have had major surgery or a serious injury within 14 days before starting the study.
• You have received chemotherapy, radiation, or certain targeted cancer drugs too recently before starting the study (specific waiting periods apply depending on the type of treatment — confirm with trial site).
• You are currently taking steroids at a dose higher than the equivalent of 10 mg of prednisone per day on a regular basis (short-term use for nausea is an exception).
• You are currently taking part in another clinical trial that involves an active treatment.
• You are pregnant or currently breastfeeding.
• You have any other medical, personal, or life circumstance that, in your doctor's judgment, might make it difficult to safely participate in or complete the study.

Important: Always verify eligibility with the trial site directly before applying.